ACKRELL CAPITAL Cannabis Investment Report | December 2017 Greece announced in 2017 that the use of cannabis extracts would be permitted for patients who obtain a doctor’s recommendation and are diagnosed with chronic pain, neuropathic pain, chemo- therapy-induced nausea, certain eating disorders and cancer. In the United Kingdom, the Misuse of Drugs Act 1971 (Drugs Act) generally prohibits the manu- facture, supply and possession of any “controlled drug,” including cannabis and cannabis resin, with- out a license issued by the Home Office, a ministerial department of the U.K. government. There is no exception to this general Drugs Act prohibition that would facilitate patient access to cannabis or concentrates for treating specified medical conditions. However, within the Drugs Act framework, the Home Office has issued to U.K.-based GW Pharmaceuticals licenses to cultivate, possess and supply cannabis for medical research and for commercial purposes. GW Pharmaceuticals produces Sativex, a mouth spray that contains cannabis-derived THC and CBD and is used for treatment of spasticity caused by multiple sclerosis. Sativex is generally recognized as the first prescription drug in the world to include plant-based cannabinoids. It was first approved for use in the U.K. in 2010 and has been approved for use in at least 30 countries (but not in the United States). Middle East, Asia and Africa Throughout the Middle East, Asia and Africa, cannabis cultivation, sale and possession generally remain prohibited and punishable as criminal offenses. Only a handful of countries from these regions have enacted laws that decriminalize possession of small amounts of cannabis for personal use or facil- itate patient access to cannabis or concentrates for treating specified medical conditions. In 2017, particular sections of South Africas Drugs and Drug Trafficking Act, which prohibit cul- tivation, possession and personal use of cannabis on private property, were declared unconsti